Cefuroxime is a parenteral or oral second-generation cephalosporinantibiotic. This antibiotic was discovered by the Glaxo company, now GlaxoSmithKline, and it was first marketed in 1978 as Zinacef. Zinacef was approved by the U.S. Food and Drug Administration on Oct 19, 1983. The generic form of cefuroxime is also called "Ceftin". The 17-year patent for this antibiotic has now expired in the United States, hence the patent "rights" to produce this medication are now irrelevant.
In the United States this antibiotic is also sold as "Zinacef" by Covis Pharmaceuticals. In India, this antibiotic is sold as Supacef by GSK.
Cefuroxime axetil is an acetoxyetyl-ester-prodrug of cefuroxime which is effective orally. In Bangladesh, this drug is available as Xorimax by Sandoz, Turbocef by Beximco Pharmaceuticals Limited.
Cefuroxime is generally well-tolerated and its side effects are usually transient. If ingested after food, this antibiotic is both better absorbed and less likely to cause its most common side effects of diarrhea, nausea, vomiting, headaches/migraines, dizziness, and abdominal pain compared to most antibiotics in its class.
Although there is a widely-stated crossallergic risk of about 10 percent between cephalosporins and penicillin, recent assessments have shown no increased risk for a crossallergic reaction for cefuroxime and several other second-generation or later cephalosporins.